Study of Vemurafenib Combined With a MEK Inhibitor

July 23, 2015
Anna C. Pavlick, DO

Anna C. Pavlick, DO, co-director, Melanoma Program, assistant director, Clinical Research Education, associate professor, Departments of Medicine and Dermatology, Langone Medical Center, New York University, discusses the study of vemurafenib combined with a MEK inhibitor.

Pavlick believes the combination studies have provided more confidence for treating patients, who have a very aggressive disease, with combination therapy, instead of immunotherapy.

The toxicities were very tolerable and less than expected.

Anna C. Pavlick, DO, co-director, Melanoma Program, assistant director, Clinical Research Education, associate professor, Departments of Medicine and Dermatology, Langone Medical Center, New York University, discusses the study of vemurafenib combined with a MEK inhibitor.